Literature DB >> 9179360

Differences in the apoptosis-inducing properties of Viscum album L. extracts.

A Büssing1, K Suzart, K Schweizer.   

Abstract

Viscum album L. (mistletoe) extracts are widely used in adjuvant cancer therapy. In contrast to purified components, such as mistletoe lectins and viscotoxins, whole plant extracts of mistletoe resulted in DNA stabilizations in cyclophosphamide-treated lymphocytes but also provided cytotoxicity in tumour cells and lymphocytes. The killing capacities of mistletoe extracts were host tree-specific and not correlated with mistletoe lectin or viscotoxin content. In human lymphocytes, only mistletoe lectins induced a pathway of apoptotic killing. Within 72 h, the lectin B chains also increased the number of lymphocytes undergoing apoptosis. This finding suggests that inhibition of protein synthesis by the A chain of the hololectin may accelerate a receptor-mediated killing pathway induced by the B chains. An unexpected finding was related to the mistletoe-mediated killing, which was more effective against CD8+T cells with an activated phenotype than CD19+ B cells and CD4+ T cells. In vitro treatment of human neutrophils with mistletoe resulted in a slight decrease of phagocytosis and burst activity. The observed dose-dependent occurrence of two neutrophil subsets with different burst activities indicates differences in their susceptibility to mistletoe and suggests the implication of an induction of the apoptotic killing pathway.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9179360     DOI: 10.1097/00001813-199704001-00003

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  8 in total

1.  Survival of cancer patients treated with mistletoe extract (Iscador): a systematic literature review.

Authors:  Thomas Ostermann; Christa Raak; Arndt Büssing
Journal:  BMC Cancer       Date:  2009-12-18       Impact factor: 4.430

2.  Viscotoxin and lectin content in foliage and fruit of Viscum album L. on the main host trees of Hyrcanian forests.

Authors:  Sanaz Yousefvand; Farnoosh Fattahi; Seyed Mohsen Hosseini; Konrad Urech; Gerhard Schaller
Journal:  Sci Rep       Date:  2022-06-20       Impact factor: 4.996

3.  Suppressive effect of a standardized mistletoe extract on the expression of activatory NK receptors and function of human NK cells.

Authors:  Soo Jung Lee; Young-Ok Son; Hyunjin Kim; Joo-Young Kim; Soon-Won Park; Jae-Ho Bae; Hyung Hoi Kim; Eun-Yup Lee; Byung-Seon Chung; Sun-Hee Kim; Chi-Dug Kang
Journal:  J Clin Immunol       Date:  2007-05-25       Impact factor: 8.317

4.  Quality of life and related dimensions in cancer patients treated with mistletoe extract (iscador): a meta-analysis.

Authors:  Arndt Büssing; Christa Raak; Thomas Ostermann
Journal:  Evid Based Complement Alternat Med       Date:  2011-06-14       Impact factor: 2.629

5.  Mistletoe-Based Drugs Work in Synergy with Radio-Chemotherapy in the Treatment of Glioma In Vitro and In Vivo in Glioblastoma Bearing Mice.

Authors:  Sonja Schötterl; Jennifer T Miemietz; Elena I Ilina; Naita M Wirsik; Ingrid Ehrlich; Andrea Gall; Stephan M Huber; Hans Lentzen; Michel Mittelbronn; Ulrike Naumann
Journal:  Evid Based Complement Alternat Med       Date:  2019-07-03       Impact factor: 2.629

6.  Fermented mistletoe extract as a multimodal antitumoral agent in gliomas.

Authors:  Oliver Podlech; Patrick N Harter; Michel Mittelbronn; Simone Pöschel; Ulrike Naumann
Journal:  Evid Based Complement Alternat Med       Date:  2012-10-22       Impact factor: 2.629

7.  Low-dose mistletoe lectin-I reduces melanoma growth and spread in a scid mouse xenograft model.

Authors:  A Thies; P Dautel; A Meyer; U Pfüller; U Schumacher
Journal:  Br J Cancer       Date:  2007-11-20       Impact factor: 7.640

8.  Differential Effects of Viscum album Preparations on the Maturation and Activation of Human Dendritic Cells and CD4⁺ T Cell Responses.

Authors:  Chaitrali Saha; Mrinmoy Das; Emmanuel Stephen-Victor; Alain Friboulet; Jagadeesh Bayry; Srini V Kaveri
Journal:  Molecules       Date:  2016-07-14       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.